85%Confidence
0Views
FDASource
2026-03-30Date
Summary
Zydus Pharmaceuticals faces a Class II FDA recall for Icosapent Ethyl Capsules due to oxidation causing visible defects, indicating potential quality control issues in the manufacturing process. This could impact patient trust and market share for this cardiovascular drug, especially given the competitive landscape for omega-3 acid ethyl ester medications.
Actionable: Monitor Zydus Pharmaceuticals' stock and consider reviewing positions in pharmaceutical companies relying on Softgel Healthcare Pvt. Ltd. as a contract manufacturer.
AI Confidence: 85%
Data Points
firmZydus Pharmaceuticals (USA) Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productIcosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharma
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now